Your search for bevacizumab returned 137 results

Your search for bevacizumab returned 137 results

Sort Results:

Relevant Recent
News

Bevacizumab Combo Improves Colorectal Cancer Survival

The addition of bevacizumab to combination chemotherapy for the treatment of stage IV colorectal cancer increases overall survival, particularly for patients receiving irinotecan-based chemotherapy regimens, but is associated with increased rates of strokes and gastrointestinal (GI) perforations, according to a study published online January 17 in the Journal of Clinical Oncology.
Drug News

Long Term Study Tests Anti-VEGF Agents Influences on Sight

For patients with diabetic macular edema (DME), visual acuity (VA) improves over two years with treatment with different anti-vascular endothelial growth factor (VEGF) agents, according to a study published online in Ophthalmology.
News

Adjuvant Bevacizumab Ups Progression-Free Survival

The addition of bevacizumab to trastazumab and docetaxel is associated with an increase in progression-free survival in patients with human epidermal growth factor receptor 2 (HER2)-positive, locally recurrent/metastatic breast cancer.
Uncategorized

Sterility Issues with Avella’s Injectables

Avella Specialty Pharmacy announced a voluntary recall of Bevacizumab 1.25mg/0.05mL PF and Vancomycin PF (BSS) 1% due to lack of sterility assurance.
Drugs in the Pipeline

Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer

Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.